For the Inventor, By the Inventor

Enter inventor name

Emeryville, CA, United States of America

Cheng Liu

USPTO Granted Patents = 46 (Patent Applications = 18)

CIPO Patents = 1 (Patent Applications = 19)

EPO Patents = 15 (Patent Applications = 37)

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 179(Granted Patents)

Location History:

Richmond, CA (US) (2011)
Orinda, CA (US) (2022)
Oakland, CA (US) (2015 - 2023)
Emeryville, CA (US) (2018 - 2024)

Company Filing History:

Eureka Therapeutics, Inc.

Memorial Sloan Kettering Cancer Center

Novartis Vaccines & Diagnostics, Gmbh

Xoma Technology Ltd.

Invisishield Technologies Ltd.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Monoclonal Antibodies

T Cell Receptor-Like Antibodies

G-Protein Coupled Receptor

B-Cell Maturation Antigen

Viral Infections

Immune Modulating Agents

Bi-Specific Antibodies

Nucleic Acid Molecules

Oncogene Products

Mucoadhesive Peptides

Modified Host Cells

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12460193 - Compositions for preventing or treating coronavirus infections (2025-11-04),

2. 12459988 - Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections (2025-11-04),

3. 12139538 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2024-11-12),

4. 11976105 - Antibody/T-cell receptor chimeric constructs and uses thereof (2024-05-07),

5. 11866478 - Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor (2024-01-09),

6. 11820806 - Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof (2023-11-21),

7. 11725059 - Antibodies targeting B-cell maturation antigen and methods of use (2023-08-15),

8. 11673957 - Anti-ROR2 antibodies (2023-06-13),

9. 11566071 - Nucleic acid molecules encoding anti-GPRC5D antibodies (2023-01-31),

10. 11505599 - T cell receptor-like antibodies specific for Foxp3-derived peptides (2022-11-22),

11. 11440952 - Compositions for preventing or treating viral and other microbial infections (2022-09-13),

12. 11421013 - Antibody/T-cell receptor chimeric constructs and uses thereof (2022-08-23),

13. 11384144 - T cell receptor-like antibodies specific for a PRAME peptide (2022-07-12),

14. 11242405 - Monoclonal antigen-binding proteins to intracellular oncogene products (2022-02-08),

15. 11168150 - T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA (2021-11-09),

Title: The Innovative Journey of Cheng Liu

Introduction: Cheng Liu, a pioneering inventor based in Emeryville, CA, has made significant contributions to the field of technology and innovation through his groundbreaking inventions and patents.

Latest Patents: Cheng Liu holds several patents in the areas of biotechnology and medical devices, with his most recent patent focusing on a novel drug delivery system that has the potential to revolutionize the pharmaceutical industry.

Career Highlights: With a background in bioengineering, Cheng Liu has a successful track record of developing cutting-edge solutions to complex medical challenges. His career highlights include the development of a minimally invasive surgical device that has improved patient outcomes and recovery times.

Collaborations: Cheng Liu has collaborated with leading research institutions and pharmaceutical companies to further advance his inventions and bring them to market. His collaborative efforts have resulted in innovative solutions that have the potential to positively impact the lives of many.

Conclusion: Cheng Liu's dedication to innovation and his passion for creating solutions to improve healthcare have solidified his reputation as a visionary inventor in the field. His continued commitment to pushing the boundaries of technology underscores his status as a true trailblazer in the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…